Canopy Growth (CGC) Total Non-Current Liabilities (2017 - 2025)
Canopy Growth's (CGC) quarterly Total Non-Current Liabilities came in at $231.8 million in Q4 2025, down 44.22% year-on-year from $415.6 million in Q4 2024, and up 3.77% quarter-over-quarter from $223.4 million in Q3 2025.
Canopy Growth (CGC) Total Non-Current Liabilities (2017 - 2025) Analysis & Trends
Canopy Growth has disclosed Total Non-Current Liabilities across 9 years of filings, most recently posting $231.8 million for Q4 2025.
- Total Non-Current Liabilities for Q4 2025 came in at $231.8 million, down 44.22% year-over-year; the trailing twelve-month figure through Dec 2025 was $231.8 million (down 44.22% YoY), and the FY2025 annual result was $274.7 million, down 49.15% from the prior year.
- Total Non-Current Liabilities came in at $231.8 million for Q4 2025 at Canopy Growth, up from $223.4 million in the prior quarter.
- In the past five years, Total Non-Current Liabilities ranged from a high of $2.4 billion in Q1 2021 to a low of $223.4 million in Q3 2025.
- The 5-year median for Total Non-Current Liabilities is $772.6 million (2023), against an average of $960.1 million.
- Across the five-year window, Total Non-Current Liabilities surged 122450.02% in 2021 and sank 56.29% in 2025, its largest moves.
- Canopy Growth's Total Non-Current Liabilities stood at $1.5 billion in 2021, then decreased by 24.76% to $1.1 billion in 2022, then tumbled by 51.98% to $545.1 million in 2023, then declined by 23.76% to $415.6 million in 2024, then sank by 44.22% to $231.8 million in 2025.
- The last three Total Non-Current Liabilities figures came in at $231.8 million (Q4 2025), $223.4 million (Q3 2025), and $279.8 million (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn | 18.28 Bn |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn | 11.64 Bn |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn | 599.10 Mn |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn | 44.12 Mn |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn | 1.24 Bn |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn | 6.26 Bn |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn | 2.44 Bn |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn | 1.81 Bn |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn | 1.13 Bn |
| 10 | Canopy Growth | 11.38 Mn | -137.31 Mn | 15.39 Mn | 231.82 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 231.82 Mn |
| Sep 30, 2025 | 223.39 Mn |
| Jun 30, 2025 | 279.78 Mn |
| Mar 31, 2025 | 274.73 Mn |
| Dec 31, 2024 | 415.58 Mn |
| Sep 30, 2024 | 511.10 Mn |
| Jun 30, 2024 | 530.14 Mn |
| Mar 31, 2024 | 540.27 Mn |
| Dec 31, 2023 | 545.09 Mn |
| Sep 30, 2023 | 618.71 Mn |
| Jun 30, 2023 | 926.46 Mn |
| Mar 31, 2023 | 1.21 Bn |
| Dec 31, 2022 | 1.14 Bn |
| Sep 30, 2022 | 1.23 Bn |
| Jun 30, 2022 | 1.42 Bn |
| Mar 31, 2022 | 1.42 Bn |
| Dec 31, 2021 | 1.51 Bn |
| Sep 30, 2021 | 1.64 Bn |
| Jun 30, 2021 | 2.10 Bn |
| Mar 31, 2021 | 2.44 Bn |